Monopar Therapeutics (NASDAQ:MNPR) Stock Price Down 5.7% - Should You Sell?

Key Points

• Monopar Therapeutics shares fell 5.7% to about $96.88 on Friday, with trading volume roughly 75% below the average session volume. The stock remains below its 50-day moving average of $111.93 but above its 200-day average of $80.60.
• Analyst sentiment remains broadly positive: the stock carries a “Moderate Buy” consensus rating and a $120.08 average price target, despite one “Sell” rating. Recent target increases include BTIG Research at $133 and Morgan Stanley at $130.
• The clinical-stage cancer biotechnology company slightly beat quarterly EPS expectations, reporting a loss of $0.62 per share versus the anticipated $0.64 loss. However, directors recently sold shares under pre-arranged Rule 10b5-1 plans, and the company is expected to post a full-year loss of $2.94 per share.

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) fell 5.7% during trading on Friday . The company traded as low as $97.00 and last traded at $96.8750. Approximately 52,451 shares traded hands during mid-day trading, a decline of 75% from the average session volume of 212,361 shares. The stock had previously closed at $102.70.

Analyst Ratings Changes

A number of research analysts have issued reports on MNPR shares. BTIG Research upped their target price on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. HC Wainwright raised their price objective on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a "buy" rating in a research note on Wednesday, July 22nd. UBS Group set a $125.00 target price on shares of Monopar Therapeutics in a research report on Thursday, July 23rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Finally, Morgan Stanley reaffirmed an "overweight" rating and set a $130.00 price objective on shares of Monopar Therapeutics in a research note on Monday, August 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $120.08.

Monopar Therapeutics Trading Down 5.6%

The business has a 50 day moving average of $111.93 and a 200-day moving average of $80.60. The firm has a market capitalization of $650.55 million, a P/E ratio of -44.64 and a beta of 1.49.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($0.64) by $0.02. On average, analysts anticipate that Monopar Therapeutics Inc. will post -2.94 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Kim R. Tsuchimoto sold 4,090 shares of the firm's stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $111.39, for a total value of $455,585.10. Following the completion of the sale, the director directly owned 7,396 shares of the company's stock, valued at $823,840.44. This trade represents a 35.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Raymond Anderson sold 3,142 shares of the firm's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total value of $351,181.34. Following the sale, the director directly owned 23,751 shares of the company's stock, valued at $2,654,649.27. This represents a 11.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Monopar Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new stake in Monopar Therapeutics in the 4th quarter valued at about $86,000. Your Advocates Ltd. LLP bought a new position in shares of Monopar Therapeutics in the 1st quarter valued at $183,000. The Manufacturers Life Insurance Company bought a new position in Monopar Therapeutics in the first quarter valued at about $250,000. Sei Investments Co. grew its holdings in shares of Monopar Therapeutics by 9.5% during the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company's stock valued at $415,000 after purchasing an additional 656 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Monopar Therapeutics during the fourth quarter worth $654,000. Institutional investors and hedge funds own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. The company's programs are designed to address significant limitations associated with existing cancer therapies, including treatment resistance and dose-limiting toxicity.

Monopar's lead clinical program is camsirubicin, an investigational next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The drug is designed to retain the anticancer activity of anthracyclines while reducing the risk of cumulative heart damage associated with conventional doxorubicin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.